Market Research Report
Stem Cell Therapy Market, by Types, by Application, by Cell Source, by End-Use, and by Geography - Analysis, Share, Trends, Size, & Forecast From 2020 - 2026
|Stem Cell Therapy Market, by Types, by Application, by Cell Source, by End-Use, and by Geography - Analysis, Share, Trends, Size, & Forecast From 2020 - 2026|
Published: March 1, 2020
AnalystView Market Insights
Content info: 206 Pages
Delivery time: 2-3 business days
The stem cell therapy market was valued at USD XX billion by 2018, growing with XX% CAGR during the forecast period, 2020-2026
Stem cell therapy is a rapidly advancing branch of medicine that involves repair and regeneration of tissues to improve the organ function. This therapy has gained global recognition as one of the promising breakthroughs in natural healing and renewal. Stem cell therapy is used for the treatment of various life-threatening disorders such as diabetes, spinal cord injuries Parkinson's & Alzheimer's disease, cancer, heart disease, and osteoarthritis. Advancements and innovation in stem cell therapy has been trending subject in the past decade. Stem cell research also includes collecting data and using the data to benefit potential organ transplant patients.
One of the biggest applications of stem cell therapy is its use in organ transplant and tissue regeneration. According to the National Centre of Biotechnology Information (August 2017), cell therapy has been showing promising results in solid organ transplantation and is known to be safe and feasible in clinical trials. Thus, the demand for stem cell therapy is anticipated to increase in future. In addition to this, rising number for patients demanding organ transplantation support the industry growth. Based on data published in a National Stem Cell Foundation (NSCF), approximately 115,000 patients are on the waitlist for life-saving organ transplantation surgeries.
Furthermore, a transplant study led by DRI Federation center at Xiamen University in China and scientists from the Diabetes Research Institute at the Miller School showed that mesenchymal stem cells exhibits strong potential to replace a powerful anti-rejection therapeutics in transplant recipient. This study was published by the University of Miami Health System in February 2020. This benefits remains the key driver for the growth of the stem cell therapy industry. On the other side, unclear and ambiguous regulatory guidelines for stem cell research and application will pull back the industry growth to some extent.
In terms of types, the industry is segmented as autologous, and allogeneic stem cell therapy. Among these, the allogeneic stem cell therapy dominates the worldwide stem cell therapy market. The primary reason why allogeneic stem cell therapy governs this market is due to its wide range of applications and its ease of commercialization in clinical trials. An article published in 'healio.com' (December 2018) stated, that allogeneic therapy helps in reducing the risk of relapsed follicular lymphoma.
In terms of application, the stem cell therapy industry is broadly studied into CNS diseases, oncology, eye diseases¸ wound & injuries, musculoskeletal diseases, metabolic disorders, CVS and immune system disorders. Among the mentioned applications, the CNS category held the largest market share owing to the rising CNS disorders coupled with lack of effective treatment therapies. In November 2017, the article published by the Biopharma Dealmakers stated that there is a lack of successful curative therapies for the treatment of Alzheimer's, Huntington's, and Parkinson's disease. This stem cell therapy has uplifted and firmly positioned its use to replace the damaged neurons thereby offers great hope for patients with neurodegenerative disorders.
Cell Source Takeaway
Based on the cell source segment, the industry is segmented into bone marrow-derived, adipose tissue-derived mesenchymal, and cord blood/embryonic stem cells. Within this category, the adipose tissue-derived segment accounted for maximum revenue share in 2018 and is projected to grow with promising growth rate during the forecast period. With respect to the fastest-growing category, bone marrow-derived means in mesenchymal stem cell leads undoubtedly. This cell source types are essential in providing support to the differentiation and growth of primitive hemopoietic tissues within the bone marrow microenvironment.
Hospitals and ambulatory surgical centres are the two end-users category analysed in this report. Among which, hospitals captured significant revenue share in 2018 and is anticipated to continue its dominance over the study period. Whereas, ambulatory surgical centres will be the fastest growing category during the projection period. Availability of centres such as Advanced Ambulatory Surgery Center (AASC) that offers world-class facility to physicians to perform stem cell procedures supports the segment growth to certain extent.
Regionally, the North America is the most developed and dominant market with regards to stem cell therapy. This can be attributed to the rising research and development activity in the U.S market. Earlier, President Clinton had signed a law that banned Federal funding in research that was associated with destroying human embryos. In March 2019, then President Mr Obama issued an order that would favor the human embryonic stem cell research. In addition to this, as per the Charlotte Lozier Institute website (February 2018), approximately USD 131 million were allocated to human embryonic stem cell research whereas, 861 million dollar was attributed to non-embryonic stem cell research. Such favourable government initiatives would in turn help this region to grow considerably and provides path-breaking discoveries in the regenerative medicine category. The Asia Pacific follows the lead and is expected to be one of the fastest-growing markets over the forecast.
Key Vendor Takeaway
The key players that dominate the market in this category are, Mesoblast Ltd., Vericel Corporation, Gamida Cell, Stem Cells, Inc., Chiesi Farmaceutici S.p.A., Osiris Therapeutics, Inc. and ReNeuron Group, plc. Osiris therapeutics announced the completion of its acquisition by a Smith and Nephew PLC. In fact, in 2015, Chiesi Pharmaceutical drug that is an advanced stem cell therapy based medicinal product which is first of its kind was approved in Europe.
The market size and forecast for each segment and sub-segments has been considered as below:
Historical Year - 2015 to 2018
Base Year - 2019
Estimated Year - 2020
Projected Year - 2026
Traders, Distributors, and Suppliers
Government and Regional Agencies
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
Stem Cells, Inc.
Chiesi Farmaceutici S.p.A.
Osiris Therapeutics, Inc.
ReNeuron Group, plc.
MARKET, BY TYPES
Autologous Stem Cell Therapy
Allogeneic Stem Cell Therapy
MARKET, BY APPLICATION
Wound & Injuries
Central Nervous System Diseases
Immune System Disorders
MARKET, BY CELL SOURCE
Cord Blood/Embryonic Stem Cells
Adipose Tissue-derived Mesenchymal Stem Cells
Bone Marrow-derived Mesenchymal Stem Cells
Other Cell Sources
MARKET, BY END-USE
Ambulatory Surgical Centers
MARKET, BY REGION
Rest of Europe
Rest of APAC
Rest of LATAM
Middle East and Africa
United Arab Emirates
Rest of MEA